William Blair Has Negative Forecast for KROS Q2 Earnings

Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Equities research analysts at William Blair cut their Q2 2025 earnings per share (EPS) estimates for Keros Therapeutics in a research report issued to clients and investors on Tuesday, May 6th. William Blair analyst M. Phipps now forecasts that the company will earn ($1.08) per share for the quarter, down from their prior estimate of ($0.81). The consensus estimate for Keros Therapeutics' current full-year earnings is ($4.74) per share. William Blair also issued estimates for Keros Therapeutics' Q3 2025 earnings at ($0.83) EPS, Q4 2025 earnings at ($0.74) EPS, FY2025 earnings at $0.51 EPS, Q1 2026 earnings at ($0.77) EPS, Q2 2026 earnings at ($0.78) EPS, Q3 2026 earnings at ($0.78) EPS, Q4 2026 earnings at ($0.78) EPS, FY2026 earnings at ($3.11) EPS, FY2027 earnings at ($2.90) EPS and FY2028 earnings at ($2.63) EPS.

Other analysts have also issued research reports about the company. Scotiabank dropped their price target on Keros Therapeutics from $44.00 to $41.00 and set a "sector outperform" rating for the company in a research note on Thursday, January 16th. Cantor Fitzgerald lowered Keros Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Tuesday, January 21st. HC Wainwright dropped their price target on Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating for the company in a research note on Thursday. Wells Fargo & Company dropped their price target on Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday, February 27th. Finally, Oppenheimer dropped their price target on Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating for the company in a research note on Thursday, January 16th. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat, Keros Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $38.67.

Keros Therapeutics Stock Performance

KROS stock traded down $0.37 on Friday, reaching $13.65. The company's stock had a trading volume of 546,340 shares, compared to its average volume of 823,532. The business has a fifty day simple moving average of $12.20 and a two-hundred day simple moving average of $24.23. Keros Therapeutics has a 12-month low of $9.12 and a 12-month high of $72.37. The firm has a market cap of $554.39 million, a PE ratio of -2.62 and a beta of 1.32.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $3.62 EPS for the quarter, topping analysts' consensus estimates of ($0.01) by $3.63. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company had revenue of $211.25 million during the quarter, compared to analyst estimates of $84.62 million. During the same quarter last year, the firm posted ($1.21) earnings per share.

Institutional Investors Weigh In On Keros Therapeutics

Several large investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in Keros Therapeutics by 31.1% in the 1st quarter. Vanguard Group Inc. now owns 2,566,321 shares of the company's stock worth $26,151,000 after buying an additional 609,212 shares in the last quarter. Braidwell LP increased its holdings in Keros Therapeutics by 167.9% in the 4th quarter. Braidwell LP now owns 1,894,439 shares of the company's stock worth $29,989,000 after buying an additional 1,187,199 shares in the last quarter. Darwin Global Management Ltd. increased its holdings in Keros Therapeutics by 10.7% in the 4th quarter. Darwin Global Management Ltd. now owns 1,687,135 shares of the company's stock worth $26,707,000 after buying an additional 163,403 shares in the last quarter. Federated Hermes Inc. increased its holdings in Keros Therapeutics by 882.3% in the 1st quarter. Federated Hermes Inc. now owns 1,224,139 shares of the company's stock worth $12,474,000 after buying an additional 1,099,519 shares in the last quarter. Finally, Millennium Management LLC increased its holdings in Keros Therapeutics by 53.3% in the 4th quarter. Millennium Management LLC now owns 878,159 shares of the company's stock worth $13,901,000 after buying an additional 305,169 shares in the last quarter. 71.56% of the stock is currently owned by institutional investors.

Insider Activity

In related news, major shareholder Adar1 Capital Management, Llc purchased 934,258 shares of Keros Therapeutics stock in a transaction dated Wednesday, April 9th. The stock was purchased at an average cost of $10.13 per share, for a total transaction of $9,464,033.54. Following the completion of the acquisition, the insider now directly owns 4,392,737 shares of the company's stock, valued at $44,498,425.81. The trade was a 27.01% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 20.60% of the company's stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.